Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.
The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site.
The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).
The warning letter was issued in response to a request for records pursuant to a section of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any on-site inspection of the facility by the US FDA.
The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.
'We believe that the said warning letter will not impact current operations and supplies from the Baddi site,” Zydus Lifesciences said in a statement.
The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025.
Subsequent to the conclusion of the inspection, the company received the establishment inspection report (EIR) in October 2025, with the final compliance status classified as voluntary action indicated (VAI).
Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company’s consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.
Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.24% on the day, quoting at 23849.9. The Sensex is at 75777.13, down 0.12%. Zydus Lifesciences Ltd has added around 23.94% in last one month.
Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.44% in last one month and is currently quoting at 24716, up 0.2% on the day. The volume in the stock stood at 14.03 lakh shares today, compared to the daily average of 23 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1114.05, up 2.08% on the day. Zydus Lifesciences Ltd is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma index.
The PE of the stock is 29.59 based on TTM earnings ending March 26.
Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026.
In June 2025 under Tranche 1, the company and its subsidiaries had invested Rs 3.86 crore for subscription of 38,64,792 equity shares of Torrent Urja 25, representing 22.06% of its paid-up share capital.
For the full year,net profit rose 11.37% to Rs 5040.00 crore in the year ended March 2026 as against Rs 4525.50 crore during the previous year ended March 2025. Sales rose 18.37% to Rs 26719.70 crore in the year ended March 2026 as against Rs 22573.80 crore during the previous year ended March 2025.
EBITDA stood at Rs 2,554.4 crore in Q4 FY26, registering the growth of 20.2% compared with Rs 2,125.5 crore in Q4 FY25. EBITDA margin improved to 33.7% in Q4 FY26 as against 32.6% in Q4 FY25. The company’s organic capital expenditure for the quarter stood at Rs 357.7 crore.
Revenue from India formulation business jumped 14% YoY to Rs 1,752.8 crore, contributing 24% to consolidated revenue. Branded business grew faster than the market with 15% YoY growth.
North America formulation business registered revenues of Rs 2,952.3 crore, down 6% YoY and accounted for 40% of consolidated revenue. In constant currency terms, the business posted revenue of $323 milion.
Revenue from international markets formulation business stood at Rs 804.1 crore, up 45% YoY. The business accounted for 11% of consolidated revenues. The growth was broad-based across regions, led by robust demand in emerging markets and Europe, aided by focused execution
Revenue from consumer wellness business climbed 61% YoY to Rs 1,463.3 crore. Domestic business grew by 1.7% YoY. Within the domestic business, the seasonal brands declined by 9.8%, whereas the skin & hair care brands and food & nutrition brands registered 39.7% and 9.4% YoY growth respectively.
On full year basis, the company’s consolidated net profit jumped 11.37% to Rs 5,040 crore in FY26 compared with Rs 4,525.5 crore in FY25. Revenue from operations increased 16.81% to Rs 27,148.4 crore in FY26 compared with Rs 23,241.5.
Sharvil Patel, managing director - Zydus Lifesciences , said, “We closed FY26 on a strong note, delivering on our commitments —both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near -term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.'
Meanwhile, the company’s board recommended a final dividend of Re 1 per equity share of face value Re 1 each for FY26, subject to shareholders’ approval at the forthcoming Annual General Meeting (AGM) scheduled on Tuesday, 11 August 2026. The company has fixed 24 July 2026 as the record date for determining shareholders eligible for the dividend.
Further, the board also approved a share buyback of up to 95,65,217 equity shares aggregating up to Rs 1,100 crore at a price of Rs 1,150 per share, representing a premium of 16.02% over the stock’s closing price of Rs 991.20 on 18 May 2026. The record date for the buyback has been fixed as 29 May 2026. As on 15 May 2026, promoters and the promoter group held a 74.9950% stake in the company.